User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Molecular biology of squamous cell carcinoma of the head and neck : relevance and therapeutic implications

Primary tabs

Schmitz, Sandra [UCL] Machiels, Jean-Pascal [UCL]

More than 90% of all head and neck cancers are squamous cell carcinoma. Despite advances in the management of patients with this disease, the survival rate has not been significantly improved. Several mechanisms of carcinogenesis have been elucidated and molecular targeted agents seem to be promising therapeutic tools. Cetuximab, a monoclonal antibody inhibitor of the EGF receptor, improves survival rates in association with radiotherapy in advanced squamous cell carcinoma of the head and neck (SCCHN) or in palliative disease, and is nowadays the only targeted agent approved in this indication. Other targeted agents are also clinically relevant to the treatment of different malignancies, including SCCHN. This article focuses on the major molecular pathways implicated in SCCHN carcinogenesis and provides an overview of their therapeutic implications.

  1. WILSONIII D, BOHR V, The mechanics of base excision repair, and its relationship to aging and disease, 10.1016/j.dnarep.2006.10.017
  2. Li Chunying, Hu Zhibin, Lu Jiachun, Liu Zhensheng, Wang Li-E, El-Naggar Adel K., Sturgis Erich M., Spitz Margaret R., Wei Qingyi, Genetic polymorphisms in DNA base-excision repair genesADPRT,XRCC1, andAPE1 and the risk of squamous cell carcinoma of the head and neck, 10.1002/cncr.22861
  3. Handra-Luca A., Hernandez J., Mountzios G., Taranchon E., Lacau-St-Guily J., Soria J.-C., Fouret P., Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma, 10.1158/1078-0432.ccr-07-0252
  4. Ho Tang, Wei Qingyi, Sturgis Erich M., Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck, 10.1002/hed.20570
  5. Zafereo M. E., Sturgis E. M., Liu Z., Wang L.-E, Wei Q., Li G., Nucleotide excision repair core gene polymorphisms and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck, 10.1093/carcin/bgp096
  6. Anantharaman Devasena, Chaubal Pranay M., Kannan Sadhana, Bhisey Rajani A., Mahimkar Manoj B., Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure as a risk modulator, 10.1093/carcin/bgm038
  7. Seitz, Alcohol Res. Health, 30, 38 (2007)
  8. Rosenquist Kerstin, Wennerberg Johan, Schildt Elsy-Britt, Bladström Anna, Göran Hansson Bengt, Andersson Gunilla, Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden, 10.1080/00016480510012273
  9. Kreimer A. R., Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review, 10.1158/1055-9965.epi-04-0551
  10. Fakhry Carole, Gillison Maura L., Clinical Implications of Human Papillomavirus in Head and Neck Cancers, 10.1200/jco.2006.06.1291
  11. Gillison Maura L., D'Souza Gypsyamber, Westra William, Sugar Elizabeth, Xiao Weihong, Begum Shahnaz, Viscidi Raphael, Distinct Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–Negative Head and Neck Cancers, 10.1093/jnci/djn025
  12. Narisawa-Saito Mako, Kiyono Tohru, Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins, 10.1111/j.1349-7006.2007.00546.x
  13. Slebos R. J.C., Gene Expression Differences Associated with Human Papillomavirus Status in Head and Neck Squamous Cell Carcinoma, 10.1158/1078-0432.ccr-05-2017
  14. Weinberger Paul M., Yu Ziwei, Kountourakis Panteleimon, Sasaki Clarence, Haffty Bruce G., Kowalski Diane, Merkley Mark A., Rimm David L., Camp Robert L., Psyrri Amanda, Defining Molecular Phenotypes of Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma : Validation of Three-Class Hypothesis, 10.1016/j.otohns.2009.04.014
  15. Smith Elaine M, Rubenstein Linda M, Hoffman Henry, Haugen Thomas H, Turek Lubomir P, Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer, 10.1186/1750-9378-5-4
  16. Gillison, J. Clin. Oncol., 27 (2009)
  17. Maxwell J. H., Kumar B., Feng F. Y., Worden F. P., Lee J. S., Eisbruch A., Wolf G. T., Prince M. E., Moyer J. S., Teknos T. N., Chepeha D. B., McHugh J. B., Urba S. G., Stoerker J., Walline H. M., Kurnit D. M., Cordell K. G., Davis S. J., Ward P. D., Bradford C. R., Carey T. E., Tobacco Use in Human Papillomavirus-Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence, 10.1158/1078-0432.ccr-09-2350
  18. Ragin Camille C. R., Taioli Emanuela, Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta-analysis, 10.1002/ijc.22851
  19. Fakhry C., Westra W. H., Li S., Cmelak A., Ridge J. A., Pinto H., Forastiere A., Gillison M. L., Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial, 10.1093/jnci/djn011
  20. Budrukkar, Head Neck (2009)
  21. Prime S.S., Thakker N.S., Pring M., Guest P.G., Paterson I.C., A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma, 10.1016/s1368-8375(00)00055-5
  22. Califano, Cancer Res., 56, 2488 (1996)
  23. Mao Li, Hong Waun K, Papadimitrakopoulou Vassiliki A, Focus on head and neck cancer, 10.1016/s1535-6108(04)00090-x
  24. Singh B., p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas, 10.1101/gad.973602
  25. Klussmann J. P., Mooren J. J., Lehnen M., Claessen S. M.H., Stenner M., Huebbers C. U., Weissenborn S. J., Wedemeyer I., Preuss S. F., Straetmans J. M.J.A.A., Manni J. J., Hopman A. H.N., Speel E.-J. M., Genetic Signatures of HPV-related and Unrelated Oropharyngeal Carcinoma and Their Prognostic Implications, 10.1158/1078-0432.ccr-08-1463
  26. Normanno Nicola, De Luca Antonella, Bianco Caterina, Strizzi Luigi, Mancino Mario, Maiello Monica R., Carotenuto Adele, De Feo Gianfranco, Caponigro Francesco, Salomon David S., Epidermal growth factor receptor (EGFR) signaling in cancer, 10.1016/j.gene.2005.10.018
  27. Kalyankrishna Shailaja, Grandis Jennifer R., Epidermal Growth Factor Receptor Biology in Head and Neck Cancer, 10.1200/jco.2005.04.8306
  28. Grandis Jennifer Rubin, Melhem Mona F., Gooding William E., Day Roger, Holst Valerie A., Wagener Marilyn M., Drenning Stephanie D., Tweardy David J., Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival, 10.1093/jnci/90.11.824
  29. Psyrri A., Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis, 10.1158/1078-0432.ccr-05-0420
  30. Hanada Norihisa, Lo Hui-Wen, Day Chi-Ping, Pan Yong, Nakajima Yusuke, Hung Mien-Chie, Co-regulation of B-Myb expression by E2F1 and EGF receptor, 10.1002/mc.20147
  31. Lo Hui-Wen, Hsu Sheng-Chieh, Ali-Seyed Mohamed, Gunduz Mehmet, Xia Weiya, Wei Yongkun, Bartholomeusz Geoffrey, Shih Jin-Yuan, Hung Mien-Chie, Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway, 10.1016/j.ccr.2005.05.007
  32. Hung Liang-Yi, Tseng Joseph T., Lee Yi-Chao, Xia Weiya, Wang Ying-Nai, Wu Min-Li, Chuang Yu-Hsuan, Lai Chein-Hsien, Chang Wen-Chang, Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression, 10.1093/nar/gkn417
  33. Mrhalova, Neoplasma, 52, 338 (2005)
  34. Chung Christine H., Ely Kim, McGavran Loris, Varella-Garcia Marileila, Parker Joel, Parker Natalie, Jarrett Carolyn, Carter Jesse, Murphy Barbara A., Netterville James, Burkey Brian B., Sinard Robert, Cmelak Anthony, Levy Shawn, Yarbrough Wendell G., Slebos Robbert J.C., Hirsch Fred R., Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas, 10.1200/jco.2006.07.2587
  35. Temam Stephane, Kawaguchi Hidetoshi, El-Naggar Adel K., Jelinek Jaroslav, Tang Hongli, Liu Diane D., Lang Wenhua, Issa Jean-Pierre, Lee J. Jack, Mao Li, Epidermal Growth Factor Receptor Copy Number Alterations Correlate With Poor Clinical Outcome in Patients With Head and Neck Squamous Cancer, 10.1200/jco.2006.06.6605
  36. Chiang Wei-Fan, Liu Shyun-Yeu, Yen Ching-Yu, Lin Chin-Nan, Chen Yen-Chia, Lin Shu-Chun, Chang Kuo-Wei, Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas, 10.1016/j.oraloncology.2007.02.008
  37. Dittmann Klaus, Mayer Claus, Fehrenbacher Birgit, Schaller Martin, Raju Uma, Milas Luka, Chen David J., Kehlbach Rainer, Rodemann H. Peter, Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase, 10.1074/jbc.m506591200
  38. Dittmann Klaus H., Mayer Claus, Ohneseit Petra A., Raju Uma, Andratschke Nickolaus H., Milas Luka, Rodemann H. Peter, Celecoxib Induced Tumor Cell Radiosensitization by Inhibiting Radiation Induced Nuclear EGFR Transport and DNA-Repair: A COX-2 Independent Mechanism, 10.1016/j.ijrobp.2007.08.065
  39. Dittmann Klaus, Mayer Claus, Rodemann Hans-Peter, Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity, 10.1016/j.radonc.2005.06.022
  40. Walker Francesca, Zhang Hui-Hua, Burgess Antony W., Identification of a novel EGF-sensitive cell cycle checkpoint, 10.1016/j.yexcr.2006.10.026
  41. Milas, Clin. Cancer Res., 6, 701 (2000)
  42. Robert, J. Clin. Oncol., 19, 3234 (2001)
  43. Bonner James A., Harari Paul M., Giralt Jordi, Azarnia Nozar, Shin Dong M., Cohen Roger B., Jones Christopher U., Sur Ranjan, Raben David, Jassem Jacek, Ove Roger, Kies Merrill S., Baselga Jose, Youssoufian Hagop, Amellal Nadia, Rowinsky Eric K., Ang K. Kian, Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck, 10.1056/nejmoa053422
  44. Bonner James A, Harari Paul M, Giralt Jordi, Cohen Roger B, Jones Christopher U, Sur Ranjan K, Raben David, Baselga Jose, Spencer Sharon A, Zhu Junming, Youssoufian Hagop, Rowinsky Eric K, Ang K Kian, Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival, 10.1016/s1470-2045(09)70311-0
  45. Pfister David G., Su Yungpo Bernard, Kraus Dennis H., Wolden Suzanne L., Lis Eric, Aliff Timothy B., Zahalsky Andrew J., Lake Simone, Needle Michael N., Shaha Ashok R., Shah Jatin P., Zelefsky Michael J., Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm, 10.1200/jco.2004.00.1792
  46. Vermorken Jan B., Mesia Ricard, Rivera Fernando, Remenar Eva, Kawecki Andrzej, Rottey Sylvie, Erfan Jozsef, Zabolotnyy Dmytro, Kienzer Heinz-Roland, Cupissol Didier, Peyrade Frederic, Benasso Marco, Vynnychenko Ihor, De Raucourt Dominique, Bokemeyer Carsten, Schueler Armin, Amellal Nadia, Hitt Ricardo, Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer, 10.1056/nejmoa0802656
  47. Mesía, Ann. Oncol. (2010)
  48. Herbst Roy S., Arquette Matthew, Shin Dong M., Dicke Karel, Vokes Everett E., Azarnia Nozar, Hong Waun Ki, Kies Merrill S., Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck, 10.1200/jco.2005.07.120
  49. Baselga José, Trigo José M., Bourhis Jean, Tortochaux Jacques, Cortés-Funes Hernán, Hitt Ricardo, Gascón Pere, Amellal Nadia, Harstrick Andreas, Eckardt André, Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck, 10.1200/jco.2005.07.119
  50. Ahsan A., Hiniker S. M., Ramanand S. G., Nyati S., Hegde A., Helman A., Menawat R., Bhojani M. S., Lawrence T. S., Nyati M. K., Role of Epidermal Growth Factor Receptor Degradation in Cisplatin-Induced Cytotoxicity in Head and Neck Cancer, 10.1158/0008-5472.can-09-4294
  51. Machiels JP, Subramian S, Ruzsa Aet al.An open-label, randomized Phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFR) antibody, versus best supportive care in patients with non-curable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based therapy. Presented at:2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).Chicago, IL, USA, 4–8 June 2010.
  52. Cohen Ezra E.W., Role of Epidermal Growth Factor Receptor Pathway–Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck, 10.1200/jco.2005.05.4577
  53. Argiris, J. Clin. Oncol., 27 (2009)
  54. Stewart J. Simon W., Cohen Ezra E.W., Licitra Lisa, Van Herpen Carla M.L., Khorprasert Chonlakiet, Soulieres Denis, Vodvarka Pavel, Rischin Danny, Garin Avgust M., Hirsch Fred R., Varella-Garcia Marileila, Ghiorghiu Serban, Hargreaves Laura, Armour Alison, Speake Georgina, Swaisland Alan, Vokes Everett E., Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck, 10.1200/jco.2008.17.0530
  55. Grégoire V, Raben D. A Phase II randomised, double-blind, placebo-controlled study of gefitinib 250 or 500 mg given either continuously or concomitantly with cisplatin/radiotherapy for the treatment of previously untreated, unresected, late stage III/IV non-metastatic head and neck squamous cell carcinoma (Study 1839IL/0706). Presented at:2nd International Conference on Innovative Approaches in Head & Neck Oncology.Barcelona, Spain, 26–28 February 2009.
  56. Thomas F., Rochaix P., Benlyazid A., Sarini J., Rives M., Lefebvre J. L., Allal B. C., Courbon F., Chatelut E., Delord J.-P., Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma, 10.1158/1078-0432.ccr-07-1370
  57. Van Cutsem Eric, Köhne Claus-Henning, Hitre Erika, Zaluski Jerzy, Chang Chien Chung-Rong, Makhson Anatoly, D'Haens Geert, Pintér Tamás, Lim Robert, Bodoky György, Roh Jae Kyung, Folprecht Gunnar, Ruff Paul, Stroh Christopher, Tejpar Sabine, Schlichting Michael, Nippgen Johannes, Rougier Philippe, Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, 10.1056/nejmoa0805019
  58. Tsao Ming-Sound, Sakurada Akira, Cutz Jean-Claude, Zhu Chang-Qi, Kamel-Reid Suzanne, Squire Jeremy, Lorimer Ian, Zhang Tong, Liu Ni, Daneshmand Manijeh, Marrano Paula, da Cunha Santos Gilda, Lagarde Alain, Richardson Frank, Seymour Lesley, Whitehead Marlo, Ding Keyue, Pater Joseph, Shepherd Frances A., Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome, 10.1056/nejmoa050736
  59. Sok J. C., Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting, 10.1158/1078-0432.ccr-06-0913
  60. Chen L. F., Cohen E. E. W., Grandis J. R., New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors, 10.1158/1078-0432.ccr-09-2318
  61. Cavalot Andrea, Martone Tiziana, Roggero Nicolò, Brondino Gabriele, Pagano Marco, Cortesina Giorgio, Prognostic impact ofHER-2/neu expression on squamous head and neck carcinomas, 10.1002/hed.20574
  62. Ekberg, Int. J. Oncol., 26, 1177 (2005)
  63. Del Sordo Rachele, Angiero Francesca, Bellezza Guido, Cavaliere Antonio, Mameli Maria Grazia, Stefani Michele, Dessy Enrico, Sidoni Angelo, HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significance, 10.1111/j.1600-0714.2009.00815.x
  64. Zandi Roza, Larsen Alice Bjerregaard, Andersen Peter, Stockhausen Marie-Thérése, Poulsen Hans Skovgaard, Mechanisms for oncogenic activation of the epidermal growth factor receptor, 10.1016/j.cellsig.2007.06.023
  65. Abidoye, J. Clin. Oncol., 24 (2006)
  66. Torres, Invest New Drugs. (2010)
  67. Knowles L. M., Stabile L. P., Egloff A. M., Rothstein M. E., Thomas S. M., Gubish C. T., Lerner E. C., Seethala R. R., Suzuki S., Quesnelle K. M., Morgan S., Ferris R. L., Grandis J. R., Siegfried J. M., HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer, 10.1158/1078-0432.ccr-08-3252
  68. Birchmeier Carmen, Birchmeier Walter, Gherardi Ermanno, Vande Woude George F., Met, metastasis, motility and more, 10.1038/nrm1261
  69. Maulik G., Madhiwala P., Brooks S., Ma P. C., Kijima T., Tibaldi E. V., Schaefer E., Parmar K., Salgia R., Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer, 10.1111/j.1582-4934.2002.tb00453.x
  70. Molina Julian R., Adjei Alex A., The Ras/Raf/MAPK Pathway, 10.1016/s1556-0864(15)31506-9
  71. Sam Michelle R, Elliott Bruce E, Mueller Christopher R, A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells, 10.1186/1476-4598-6-69
  72. Lee K.H., Choi E.Y., Hyun M.S., Jang B.I., Kim T.N., Kim S.W., Song S.K., Kim J.H., Kim J.-R., Association of Extracellular Cleavage of E-Cadherin Mediated by MMP-7 with HGF-Induced in vitro Invasion in Human Stomach Cancer Cells, 10.1159/000101452
  73. Eisma Roselle J., Spiro Jeffrey D., Kreutzer Donald L., Role of angiogenic factors: Coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma, 10.1097/00005537-199905000-00002
  74. Hasina Rifat, Whipple Mark E, Martin Leslie E, Kuo Winston Patrick, Ohno-Machado Lucila, Lingen Mark W, Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications, 10.1038/labinvest.2008.6
  75. Akervall J., Genetic and Expression Profiles of Squamous Cell Carcinoma of the Head and Neck Correlate with Cisplatin Sensitivity and Resistance in Cell Lines and Patients, 10.1158/1078-0432.ccr-04-0722
  76. Engelman J. A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J. O., Lindeman N., Gale C.-M., Zhao X., Christensen J., Kosaka T., Holmes A. J., Rogers A. M., Cappuzzo F., Mok T., Lee C., Johnson B. E., Cantley L. C., Janne P. A., MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling, 10.1126/science.1141478
  77. Egloff Ann Marie, Grandis Jennifer R., Targeting Epidermal Growth Factor Receptor and Src Pathways in Head and Neck Cancer, 10.1053/j.seminoncol.2008.03.008
  78. Timpson P., Wilson A. S., Lehrbach G. M., Sutherland R. L., Musgrove E. A., Daly R. J., Aberrant Expression of Cortactin in Head and Neck Squamous Cell Carcinoma Cells Is Associated with Enhanced Cell Proliferation and Resistance to the Epidermal Growth Factor Receptor Inhibitor Gefitinib, 10.1158/0008-5472.can-07-0798
  79. Wheeler D L, Huang S, Kruser T J, Nechrebecki M M, Armstrong E A, Benavente S, Gondi V, Hsu K-T, Harari P M, Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members, 10.1038/onc.2008.19
  80. Sciacca Laura, Mineo Rossana, Pandini Giuseppe, Murabito Antonella, Vigneri Riccardo, Belfiore Antonino, In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A, 10.1038/sj.onc.1206058
  81. Resnicoff, Cancer Res., 55, 2463 (1995)
  82. Pollak Michael N., Schernhammer Eva S., Hankinson Susan E., Insulin-like growth factors and neoplasia, 10.1038/nrc1387
  83. Jun, J. Clin. Oncol., 27 (2009)
  84. Barnes C. J., Ohshiro K., Rayala S. K., El-Naggar A. K., Kumar R., Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer, 10.1158/1078-0432.ccr-06-2040
  85. Schmitz S, Kaminsky MC, Henry Set al.Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008–2002. Presented at:2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, USA, 4–8 June 2010.
  86. Gualberto A, Pollak M, Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions, 10.1038/onc.2009.172
  87. Huang F., Greer A., Hurlburt W., Han X., Hafezi R., Wittenberg G. M., Reeves K., Chen J., Robinson D., Li A., Lee F. Y., Gottardis M. M., Clark E., Helman L., Attar R. M., Dongre A., Carboni J. M., The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors, 10.1158/0008-5472.can-08-0835
  88. Morgillo F., Woo J. K., Kim E. S., Hong W. K., Lee H.-Y., Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib, 10.1158/0008-5472.can-06-1684
  89. Calvani M., Hypoxic induction of an HIF-1 -dependent bFGF autocrine loop drives angiogenesis in human endothelial cells, 10.1182/blood-2005-09-3541
  90. Lewis Claire E, Hughes Russell, Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2, 10.1186/bcr1679
  91. Jiang, Acta Biochim. Biophys. Sin., 39, 73 (2007)
  92. Benjamin, Development, 125, 591 (1998)
  93. Erber, FASEB J., 18, 338 (2004)
  94. Bergers Gabriele, Song Steven, Meyer-Morse Nicole, Bergsland Emily, Hanahan Douglas, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors, 10.1172/jci200317929
  95. Neuchrist Csilla, Erovic Boban M., Handisurya Alessandra, Steiner Georg E., Rockwell Patricia, Gedlicka Claudia, Burian Martin, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Expression in Squamous Cell Carcinomas of the Head and Neck : , 10.1097/00005537-200110000-00031
  96. Neuchrist Csilla, Erovic Bohan M., Handisurya Allesandra, Fischer Michael B., Steiner Georg E., Hollemann David, Gedlicka Claudia, Saaristo A., Burian Martin, Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck, 10.1002/hed.10235
  97. Kyzas P. A., Prognostic Significance of Vascular Endothelial Growth Factor Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis, 10.1158/1078-0432.ccr-04-1870
  98. Williamson, J. Clin. Oncol., 25 (2007)
  99. Elser Christine, Siu Lillian L., Winquist Eric, Agulnik Mark, Pond Gregory R., Chin Soo F., Francis Peggy, Cheiken Robin, Elting James, McNabola Angela, Wilkie Dean, Petrenciuc Oana, Chen Eric X., Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma, 10.1200/jco.2006.10.2871
  100. Machiels Jean-Pascal H., Henry Stéphanie, Zanetta Sylvie, Kaminsky Marie-Christine, Michoux Nicolas, Rommel Denis, Schmitz Sandra, Bompas Emmanuelle, Dillies Anne-Françoise, Faivre Sandrine, Moxhon Anne, Duprez Thierry, Guigay Joel, Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01, 10.1200/jco.2009.23.8584
  101. Naumov G. N., Nilsson M. B., Cascone T., Briggs A., Straume O., Akslen L. A., Lifshits E., Byers L. A., Xu L., Wu H.-k., Janne P., Kobayashi S., Halmos B., Tenen D., Tang X. M., Engelman J., Yeap B., Folkman J., Johnson B. E., Heymach J. V., Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance, 10.1158/1078-0432.ccr-08-2904
  102. Cohen Ezra EW, Davis Darren W, Karrison Theodore G, Seiwert Tanguy Y, Wong Stuart J, Nattam Sreenivasa, Kozloff Mark F, Clark Joseph I, Yan Duen-Hwa, Liu Wen, Pierce Carolyn, Dancey Janet E, Stenson Kerstin, Blair Elizabeth, Dekker Allison, Vokes Everett E, Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study, 10.1016/s1470-2045(09)70002-6
  103. Somers, Cancer Res., 52, 5997 (1992)
  104. Boyle, Cancer Res., 53, 4477 (1993)
  105. Tolcher Anthony W., Hao Desiree, de Bono Johann, Miller Alex, Patnaik Amita, Hammond Lisa A., Smetzer Leslie, Van Wart Hood Jill, Merritt James, Rowinsky Eric K., Takimoto Chris, Von Hoff Dan, Eckhardt S. Gail, Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Typep53Gene, in Patients With Advanced Cancer, 10.1200/jco.2005.03.6756
  106. Nemunaitis J., Clayman G., Agarwala S. S., Hrushesky W., Wells J. R., Moore C., Hamm J., Yoo G., Baselga J., Murphy B. A., Menander K. A., Licato L. L., Chada S., Gibbons R. D., Olivier M., Hainaut P., Roth J. A., Sobol R. E., Goodwin W. J., Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck, 10.1158/1078-0432.ccr-09-1044
  107. Moro Laura, Dolce Laura, Cabodi Sara, Bergatto Elena, Erba Elisabetta Boeri, Smeriglio Monica, Turco Emilia, Retta Saverio Francesco, Giuffrida Maria Gabriella, Venturino Mascia, Godovac-Zimmermann Jasminka, Conti Amedeo, Schaefer Erik, Beguinot Laura, Tacchetti Carlo, Gaggini Paolo, Silengo Lorenzo, Tarone Guido, Defilippi Paola, Integrin-induced Epidermal Growth Factor (EGF) Receptor Activation Requires c-Src and p130Cas and Leads to Phosphorylation of Specific EGF Receptor Tyrosines, 10.1074/jbc.m109101200
  108. Tice D. A., Biscardi J. S., Nickles A. L., Parsons S. J., Mechanism of biological synergy between cellular Src and epidermal growth factor receptor, 10.1073/pnas.96.4.1415
  109. Zhang Qing, Thomas Sufi M., Xi Sichuan, Smithgall Thomas E., Siegfried Jill M., Kamens Joanne, Gooding William E., Grandis Jennifer Rubin, Src Family Kinases Mediate Epidermal Growth Factor Receptor Ligand Cleavage, Proliferation, and Invasion of Head and Neck Cancer Cells, 10.1158/0008-5472.can-04-0504
  110. Wheeler Deric L., Iida Mar, Kruser Tim J., Nechrebecki Meghan M., Dunn Emily F., Armstrong Eric A., Huang Shyhmin, Harari Paul M., Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab, 10.4161/cbt.8.8.7903
  111. Koppikar P., Choi S.-H., Egloff A. M., Cai Q., Suzuki S., Freilino M., Nozawa H., Thomas S. M., Gooding W. E., Siegfried J. M., Grandis J. R., Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma, 10.1158/1078-0432.ccr-07-5226
  112. Brooks, J. Clin. Oncol., 27 (2009)
  113. Adams Julian, The development of proteasome inhibitors as anticancer drugs, 10.1016/s1535-6108(04)00120-5
  114. Allen Clint T., Ricker Justin L., Chen Zhong, Van Waes Carter, Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck, 10.1002/hed.20615
  115. Chen Z., Ricker J. L., Malhotra P. S., Nottingham L., Bagain L., Lee T. L., Yeh N. T., Van Waes C., Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor- B and activator protein-1 related mechanisms, 10.1158/1535-7163.mct-07-2046
  116. Li C., Zang Y., Sen M., Leeman-Neill R. J., Man D. SK., Grandis J. R., Johnson D. E., Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death, 10.1158/1535-7163.mct-09-0327
  117. Gilbert Duncan C., VanAs Nicholas J., Beesley Sharon, Bloomfield David, Money-Kyrle Julian, Norman Andy, Dearnaley David, Horwich Alan, Huddart Robert A., Treating IIA/B Seminoma With Combination Carboplatin and Radiotherapy, 10.1200/jco.2008.21.5269
  118. Amornphimoltham Panomwat, Patel Vyomesh, Sodhi Akrit, Nikitakis Nikolaos G., Sauk John J., Sausville Edward A., Molinolo Alfredo A., Gutkind J. Silvio, Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck, 10.1158/0008-5472.can-05-0921
  119. Argiris Athanassios, Cohen Ezra, Karrison Theodore, Esparaz Benjamin, Mauer Ann, Ansari Rafat, Wong Stuart, Lu Yi, Pins Michael, Dancey Janet, Vokes Everett, A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer, 10.4161/cbt.5.7.2874
  120. Morimoto, Essays Biochem., 32, 17 (1997)
  121. Yin X., Potent Activity of a Novel Dimeric Heat Shock Protein 90 Inhibitor against Head and Neck Squamous Cell Carcinoma In vitro and In vivo, 10.1158/1078-0432.ccr-04-2272
  122. Russel, Clin. Cancer Res., 9, 3749 (2003)
  123. Yin, Int. J. Cancer, 126, 1216 (2010)
Bibliographic reference Schmitz, Sandra ; Machiels, Jean-Pascal. Molecular biology of squamous cell carcinoma of the head and neck : relevance and therapeutic implications. In: Expert Review of Anticancer Therapy, Vol. 10, no. 9, p. 1471-1484 (2010)
Permanent URL http://hdl.handle.net/2078.1/33316